Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -59,248 | -47,021 | -37,260 | -19,776 | -47,762 |
| Depreciation Amortization | 130 | 96 | 66 | 32 | 154 |
| Other Working Capital | 2,460 | 1,893 | 2,912 | 2,827 | -1,241 |
| Other Operating Activity | 6,942 | 2,789 | 1,973 | 949 | 3,593 |
| Operating Cash Flow | $-49,716 | $-42,242 | $-32,309 | $-15,968 | $-45,257 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -212 | -212 | -200 | -175 | -200 |
| Net Acquisitions | -528 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $-740 | $-212 | $-200 | $-175 | $-200 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -1,034 | -722 | -410 | -102 | -3 |
| Common Stock Issued | -7 | 78 | 71 | 97 | 10,487 |
| Financing Cash Flow | $-1,041 | $-644 | $-340 | $-6 | $10,484 |
| Beginning Cash Position | 68,135 | 68,135 | 68,136 | 68,135 | 103,108 |
| End Cash Position | 16,638 | 25,037 | 35,288 | 51,986 | 68,135 |
| Net Cash Flow | $-51,497 | $-43,098 | $-32,848 | $-16,149 | $-34,973 |
| Free Cash Flow | |||||
| Operating Cash Flow | -49,716 | -42,242 | -32,309 | -15,968 | -45,257 |
| Capital Expenditure | -212 | -212 | -200 | -175 | -200 |
| Free Cash Flow | -49,928 | -42,454 | -32,509 | -16,143 | -45,457 |